The NRF2 pathway as potential biomarker for dimethyl fumarate treatment in multiple sclerosis
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The NRF2 pathway as potential biomarker for dimethyl fumarate treatment in multiple sclerosis
Authors
Keywords
-
Journal
Annals of Clinical and Translational Neurology
Volume 5, Issue 6, Pages 668-676
Publisher
Wiley
Online
2018-04-17
DOI
10.1002/acn3.553
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Monomethyl fumarate treatment impairs maturation of human myeloid dendritic cells and their ability to activate T cells
- (2017) Maria Antonietta Mazzola et al. Multiple Sclerosis Journal
- Evidence of activation of the Nrf2 pathway in multiple sclerosis patients treated with delayed-release dimethyl fumarate in the Phase 3 DEFINE and CONFIRM studies
- (2017) Sreeja Gopal et al. Multiple Sclerosis Journal
- Optimal response to dimethyl fumarate associates in MS with a shift from an inflammatory to a tolerogenic blood cell profile
- (2017) Silvia Medina et al. Multiple Sclerosis Journal
- Monomethyl fumarate treatment impairs maturation of human myeloid dendritic cells and their ability to activate T cells
- (2017) Maria Antonietta Mazzola et al. Multiple Sclerosis Journal
- Evidence of activation of the Nrf2 pathway in multiple sclerosis patients treated with delayed-release dimethyl fumarate in the Phase 3 DEFINE and CONFIRM studies
- (2017) Sreeja Gopal et al. Multiple Sclerosis Journal
- Optimal response to dimethyl fumarate associates in MS with a shift from an inflammatory to a tolerogenic blood cell profile
- (2017) Silvia Medina et al. Multiple Sclerosis Journal
- An overview of chemical inhibitors of the Nrf2-ARE signaling pathway and their potential applications in cancer therapy
- (2016) Jiayu Zhu et al. FREE RADICAL BIOLOGY AND MEDICINE
- Interferon-β therapy specifically reduces pathogenic memory B cells in multiple sclerosis patients by inducing a FAS-mediated apoptosis
- (2016) Fabiana Rizzo et al. IMMUNOLOGY AND CELL BIOLOGY
- Dimethyl Fumarate Treatment Mediates an Anti-Inflammatory Shift in B Cell Subsets of Patients with Multiple Sclerosis
- (2016) Rui Li et al. JOURNAL OF IMMUNOLOGY
- Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study
- (2016) Ralf Gold et al. Multiple Sclerosis Journal
- Nrf2–ARE pathway: An emerging target against oxidative stress and neuroinflammation in neurodegenerative diseases
- (2016) Izaskun Buendia et al. PHARMACOLOGY & THERAPEUTICS
- Dimethyl fumarate treatment induces adaptive and innate immune modulation independent of Nrf2
- (2016) Ulf Schulze-Topphoff et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study
- (2016) Ralf Gold et al. Multiple Sclerosis Journal
- S-propargyl-cysteine attenuates inflammatory response in rheumatoid arthritis by modulating the Nrf2-ARE signaling pathway
- (2016) Wei-Jun Wu et al. Redox Biology
- Dimethyl fumarate blocks pro-inflammatory cytokine production via inhibition of TLR induced M1 and K63 ubiquitin chain formation
- (2016) Victoria A. McGuire et al. Scientific Reports
- Dimethyl Fumarate Protects Neural Stem/Progenitor Cells and Neurons from Oxidative Damage through Nrf2-ERK1/2 MAPK Pathway
- (2015) Qin Wang et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Hydroxycarboxylic acid receptor 2 mediates dimethyl fumarate’s protective effect in EAE
- (2014) Hui Chen et al. JOURNAL OF CLINICAL INVESTIGATION
- Cutting Edge: Central Nervous System Plasmacytoid Dendritic Cells Regulate the Severity of Relapsing Experimental Autoimmune Encephalomyelitis
- (2014) S. L. Bailey-Bucktrout et al. JOURNAL OF IMMUNOLOGY
- Identification of aldo-keto reductases as NRF2-target marker genes in human cells
- (2013) Kyeong-Ah Jung et al. TOXICOLOGY LETTERS
- Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis
- (2012) Robert J. Fox et al. NEW ENGLAND JOURNAL OF MEDICINE
- Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
- (2012) Ralf Gold et al. NEW ENGLAND JOURNAL OF MEDICINE
- Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
- (2011) Chris H. Polman et al. ANNALS OF NEUROLOGY
- Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway
- (2011) Ralf A. Linker et al. BRAIN
- T cells in multiple sclerosis and experimental autoimmune encephalomyelitis
- (2010) J. M. Fletcher et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- A protective role of nuclear factor-erythroid 2-related factor-2 (Nrf2) in inflammatory disorders
- (2009) Jiyoung Kim et al. MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS
- The psoriasis drug monomethylfumarate is a potent nicotinic acid receptor agonist
- (2008) Hua Tang et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Interplay between mechanisms of damage and repair in multiple sclerosis
- (2008) Christine Stadelmann et al. JOURNAL OF NEUROLOGY
- Multiple sclerosis
- (2008) Alastair Compston et al. LANCET
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now